NCT03914690View on ClinicalTrials.gov

Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage

PHASE2CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Premature Infants
Interventions
DRUG

Erythropoietin

EPO is administered 500IU/kg, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.

DRUG

Normal saline

Normal saline is administered the same volume with EPO, intravenously after diagnosis of IVH within 72h after birth, and every other day for 2 weeks.

Trial Locations (1)

450052

Third Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

Zhengzhou Children's Hospital, China

OTHER

collaborator

Göteborg University

OTHER

lead

Zhengzhou University

OTHER

NCT03914690 - Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage | Biotech Hunter | Biotech Hunter